Normal range of serum Amphiregulin in healthy adult human females

Esther A. Peterson, Shabana Shabbeer, Paraic A. Kenny

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

ObjectivesPrior to large studies in breast cancer patients, we have sought to establish the normal range of a potential serum biomarker, Amphiregulin, in healthy women and to determine whether sampling during the menstrual cycle influences the detected Amphiregulin levels. Design and methodsSerum Amphiregulin levels were quantified using a commercially available ELISA in 85 normal female donors. ResultsThe range of circulating Amphiregulin was 0-4467. pg/mL. The majority of women had no detectable circulating Amphiregulin (n= 54), and only five women had levels exceeding 500. pg/mL. Serum Amphiregulin levels did not vary significantly during the menstrual cycle (n= 7 women). ConclusionsDetection of circulating Amphiregulin in a significant minority of healthy women suggests that it may not have the specificity necessary for a population screening tool; however its potential utility for monitoring response to treatment or disease progression should be examined in breast cancer cases.

Original languageEnglish (US)
Pages (from-to)460-463
Number of pages4
JournalClinical Biochemistry
Volume45
Issue number6
DOIs
StatePublished - Apr 2012

Fingerprint

Reference Values
Serum
Menstrual Cycle
Breast Neoplasms
Biomarkers
Amphiregulin
Disease Progression
Screening
Enzyme-Linked Immunosorbent Assay
Tissue Donors
Sampling
Monitoring
Population

Keywords

  • Amphiregulin
  • Breast cancer
  • Cytokine
  • Epidermal Growth Factor Receptor
  • Serum biomarker

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Normal range of serum Amphiregulin in healthy adult human females. / Peterson, Esther A.; Shabbeer, Shabana; Kenny, Paraic A.

In: Clinical Biochemistry, Vol. 45, No. 6, 04.2012, p. 460-463.

Research output: Contribution to journalArticle

Peterson, Esther A. ; Shabbeer, Shabana ; Kenny, Paraic A. / Normal range of serum Amphiregulin in healthy adult human females. In: Clinical Biochemistry. 2012 ; Vol. 45, No. 6. pp. 460-463.
@article{05209f4bd48c417d89f5bb5802084605,
title = "Normal range of serum Amphiregulin in healthy adult human females",
abstract = "ObjectivesPrior to large studies in breast cancer patients, we have sought to establish the normal range of a potential serum biomarker, Amphiregulin, in healthy women and to determine whether sampling during the menstrual cycle influences the detected Amphiregulin levels. Design and methodsSerum Amphiregulin levels were quantified using a commercially available ELISA in 85 normal female donors. ResultsThe range of circulating Amphiregulin was 0-4467. pg/mL. The majority of women had no detectable circulating Amphiregulin (n= 54), and only five women had levels exceeding 500. pg/mL. Serum Amphiregulin levels did not vary significantly during the menstrual cycle (n= 7 women). ConclusionsDetection of circulating Amphiregulin in a significant minority of healthy women suggests that it may not have the specificity necessary for a population screening tool; however its potential utility for monitoring response to treatment or disease progression should be examined in breast cancer cases.",
keywords = "Amphiregulin, Breast cancer, Cytokine, Epidermal Growth Factor Receptor, Serum biomarker",
author = "Peterson, {Esther A.} and Shabana Shabbeer and Kenny, {Paraic A.}",
year = "2012",
month = "4",
doi = "10.1016/j.clinbiochem.2011.12.029",
language = "English (US)",
volume = "45",
pages = "460--463",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Normal range of serum Amphiregulin in healthy adult human females

AU - Peterson, Esther A.

AU - Shabbeer, Shabana

AU - Kenny, Paraic A.

PY - 2012/4

Y1 - 2012/4

N2 - ObjectivesPrior to large studies in breast cancer patients, we have sought to establish the normal range of a potential serum biomarker, Amphiregulin, in healthy women and to determine whether sampling during the menstrual cycle influences the detected Amphiregulin levels. Design and methodsSerum Amphiregulin levels were quantified using a commercially available ELISA in 85 normal female donors. ResultsThe range of circulating Amphiregulin was 0-4467. pg/mL. The majority of women had no detectable circulating Amphiregulin (n= 54), and only five women had levels exceeding 500. pg/mL. Serum Amphiregulin levels did not vary significantly during the menstrual cycle (n= 7 women). ConclusionsDetection of circulating Amphiregulin in a significant minority of healthy women suggests that it may not have the specificity necessary for a population screening tool; however its potential utility for monitoring response to treatment or disease progression should be examined in breast cancer cases.

AB - ObjectivesPrior to large studies in breast cancer patients, we have sought to establish the normal range of a potential serum biomarker, Amphiregulin, in healthy women and to determine whether sampling during the menstrual cycle influences the detected Amphiregulin levels. Design and methodsSerum Amphiregulin levels were quantified using a commercially available ELISA in 85 normal female donors. ResultsThe range of circulating Amphiregulin was 0-4467. pg/mL. The majority of women had no detectable circulating Amphiregulin (n= 54), and only five women had levels exceeding 500. pg/mL. Serum Amphiregulin levels did not vary significantly during the menstrual cycle (n= 7 women). ConclusionsDetection of circulating Amphiregulin in a significant minority of healthy women suggests that it may not have the specificity necessary for a population screening tool; however its potential utility for monitoring response to treatment or disease progression should be examined in breast cancer cases.

KW - Amphiregulin

KW - Breast cancer

KW - Cytokine

KW - Epidermal Growth Factor Receptor

KW - Serum biomarker

UR - http://www.scopus.com/inward/record.url?scp=84858438619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858438619&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2011.12.029

DO - 10.1016/j.clinbiochem.2011.12.029

M3 - Article

VL - 45

SP - 460

EP - 463

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 6

ER -